Nautilus Biotechnology, INC Form 4 insider transactions

Entities affiliated with Andreessen Horowitz sold approximately 5 million shares of Nautilus Biotechnology, Inc. on June 2, 2026.

Nautilus Biotechnology's CEO, President, and Secretary, Sujal Patel, acquired 25,000 shares of common stock for approximately $65,237, signaling continued confidence in the company.

Nautilus Biotechnology's CFO and Treasurer, Anna Mowry, was granted 160,000 stock options with an exercise price of $2.32 per share, vesting over time.

Nautilus Biotechnology, Inc. has granted Chief Scientist Parag Mallick 280,000 stock options with a $2.32 exercise price, vesting over four years.

Nautilus Biotechnology's CEO, Sujal Patel, was granted 650,000 stock options with an exercise price of $2.32, vesting over four years.

Nautilus Biotechnology, Inc. granted its Senior VP of Product Development, Sankar Subramanian, 160,000 stock options with an exercise price of $2.32, vesting over several years.

Nautilus Biotechnology's Chief People Officer, Gwen E. Weld, was granted 160,000 stock options with a $2.32 exercise price, vesting over four years.

Nautilus Biotechnology's General Counsel, Matthew B. Murphy, was granted 160,000 stock options with an exercise price of $2.32, vesting over four years.

Nautilus Biotechnology's Chief Marketing Officer, Kentaro Suzuki, acquired 160,000 stock options with an exercise price of $2.32, vesting over four years.

Nautilus Biotechnology's Chief Marketing Officer, Kentaro Suzuki, purchased 4,000 shares of common stock at $1.49 per share.

Nautilus Biotechnology's CEO, Sujal Patel, has pre-planned to increase his direct beneficial ownership in the company through future stock purchases totaling 200,000 shares.

Nautilus GC Matthew Murphy plans 20,000 share acquisition.

Nautilus Biotechnology, Inc. Director Melissa B. Epperly was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Nautilus Biotechnology, Inc. Director Matthew L. Posard was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Matthew S. McIlwain, a Director at Nautilus Biotechnology, Inc., was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Nautilus Biotechnology, Inc. Director Farzad Nazem was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Nautilus Biotechnology, Inc. Director Karen Akinsanya was granted 45,000 stock options at an exercise price of $0.6951 per share, vesting monthly over a year.

Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, Inc., purchased 15,000 shares of common stock, signaling increased insider confidence.

Parag Mallick, Chief Scientist at Nautilus Biotechnology, recently purchased additional shares of the company's common stock, increasing his total holdings.

Nautilus Biotechnology's CEO, Sujal Patel, recently acquired additional shares of the company's common stock through direct purchases.

Matthew Murphy, General Counsel of Nautilus Biotechnology, acquired 160,000 stock options on March 3, 2025, according to a recent SEC filing.

Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, was granted stock options for 160,000 shares on March 3, 2025, according to a Form 4 filing.

Nicholas A. Nelson, CBO & Senior VP of Business Development at Nautilus Biotechnology, Inc., was granted stock options for 160,000 shares on March 3, 2025, according to a Form 4 filing.

Gwen Weld, Chief People Officer of Nautilus Biotechnology, acquired 160,000 stock options on March 3, 2025, according to a recent SEC filing.

Kentaro Suzuki, Chief Marketing Officer of Nautilus Biotechnology, acquired stock options for 50,000 shares of common stock on March 3, 2025, according to a recent SEC filing.

Parag Mallick, Chief Scientist of Nautilus Biotechnology, was granted stock options for 280,000 shares on March 3, 2025, according to a Form 4 filing.

Nautilus Biotechnology's CEO, Sujal M. Patel, was granted 650,000 stock options on March 3, 2025, according to a recent SEC filing.

Subramanian Sankar, Senior VP at Nautilus Biotechnology, acquires 160,000 stock options at an exercise price of $1.24, vesting over 4 years from January 1, 2025.

Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, exercised stock options and sold shares on September 23, 2024.

Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, exercised stock options and sold the resulting shares on September 17, 2024.